REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

Journal:

Nature Communications

Published:

2025-11-28

DOI:

10.1038/s41467-025-66092-1

Affiliations:

10

Authors:

24

Go to article

Institutions	Authors	Share
Erasmus MC Cancer Institute, Netherlands	15.500000 15.500000	0.65
Amphera B.V., Netherlands	2.500000	0.10
Maastricht University Medical Center+ (Maastricht UMC+), Netherlands	2.000000	0.08
Alligator Bioscience AB, Sweden	1.500000	0.06
Erasmus University Medical Center (Erasmus MC), Netherlands	1.000000	0.04
Leiden University Medical Center (LUMC), Netherlands	0.500000	0.02
Oncode Institute, Netherlands	0.500000	0.02
Lund University (LU), Sweden	0.500000	0.02

Interested in Oncology and Carcinogenesis?